No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
RCEL Avita Medical
- 8.020
- -0.110-1.35%
Close Jun 18 16:00 ET
206.91MMarket Cap-4556P/E (TTM)
8.280High7.840Low218.40KVolume8.080Open8.130Pre Close1.76MTurnover0.94%Turnover RatioLossP/E (Static)25.80MShares21.70452wk High6.35P/B187.36MFloat Cap7.51052wk Low--Dividend TTM23.36MShs Float55.350Historical High--Div YieldTTM5.41%Amplitude4.410Historical Low8.036Avg Price1Lot Size
Pre-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Avita Medical's Cell Harvesting Device Treats First US Patient; Shares Rise 5%
Avita Medical (ASX:AVH) on Thursday said the Joseph M. Still Burn Center at Doctors Hospital of Augusta, Georgia treated the first US patient using the Recell Go skin harvesting device, according to a
Express News | AVITA Medical Announces First U.S. Patient Treated With RECELL GO System At Joseph M. Still Burn Center
AVITA Medical Achieves Milestone With First Case Using RECELL GO
VALENCIA, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin
Avita Medical(RCEL.US) Officer Buys US$8,900 in Common Stock
$Avita Medical(RCEL.US)$ Officer O'Toole David D purchased 1,000 shares of common stock on May 30, 2024 at an average price of $8.9 for a total value of $8,900.Source: Announcement What is statement o
Lake Street Sticks to Their Buy Rating for Avita Medical (RCEL)
Buy Rating Affirmed: Avita Medical's Strategic Wins Promise Growth and Market Penetration
Comments
$Avita Medical(RCEL.US$
AVITA Medical Announces FDA Approval of RECELL GO
AVITA Medical announced FDA approval for its advanced autologous cell harvesting device, RECELL GO. This next-gen device improves treatment for thermal burn wounds and full-thickness skin defects by harnessing a patient's own skin. Key advantages include faster healing, reduced pain, improved aesthetics, and fewer procedures. Enhanced features streamline the preparation of Spray-On Skin Cells and improve workflow effi...
AVITA Medical Announces FDA Approval of RECELL GO
AVITA Medical announced FDA approval for its advanced autologous cell harvesting device, RECELL GO. This next-gen device improves treatment for thermal burn wounds and full-thickness skin defects by harnessing a patient's own skin. Key advantages include faster healing, reduced pain, improved aesthetics, and fewer procedures. Enhanced features streamline the preparation of Spray-On Skin Cells and improve workflow effi...
Cantor Fitzgerald sees AVITA's superior growth and high gross margins as reasons for a premium. The firm also sees potential in Pacific Biosciences and AxoGen, and expects positive share price appreciation for Exagen and NeuroPace. A significant catalyst for Nyxoah's stock is anticipated with upcoming DREAM study data.
AVITA Medical's CEO, Jim Corbett, is satisfied with the company's growth and is committed to sustaining it in 2024. The ongoing TONE study could influence future business strategies by providing insights into vitiligo's impact on patients' mental health and healthcare costs.
1
Despite strong performance, AVITA Medical's P/S ratio remains low, as investors fear possible revenue growth deceleration. The company's growth projection lags behind the industry's, potentially contributing to its low P/S ratio. Without significant revenue improvements, the stock price may stall.
Gapping up
In reaction to earnings/guidance:
• $Planet Labs PBC(PL.US$ +11.3%, $Core & Main(CNM.US$ +6.1%, $Regal Rexnord(RRX.US$ +2% (reaffirms outlook), $Oracle(ORCL.US$ +1.6%
Other news:
• $Akero Therapeutics(AKRO.US$ +93.2% (reports Phase 2b HARMONY Study)
• $Akouos(AKUS.US$ +10.3% (FDA clears IND application to initiate a Phase 1/2 first in human pediatric clinical trial of AK-OTOF)
• $Catalyst Pharmaceuticals(CPRX.US$ +7.7...
In reaction to earnings/guidance:
• $Planet Labs PBC(PL.US$ +11.3%, $Core & Main(CNM.US$ +6.1%, $Regal Rexnord(RRX.US$ +2% (reaffirms outlook), $Oracle(ORCL.US$ +1.6%
Other news:
• $Akero Therapeutics(AKRO.US$ +93.2% (reports Phase 2b HARMONY Study)
• $Akouos(AKUS.US$ +10.3% (FDA clears IND application to initiate a Phase 1/2 first in human pediatric clinical trial of AK-OTOF)
• $Catalyst Pharmaceuticals(CPRX.US$ +7.7...
10
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg